StreetInsider.com News Articles

Form 8-K ABBOTT LABORATORIES For: Oct 21

Wed, 21 Oct 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20261021/27214309.html

Abbott beats revenue estimates, shares slide amid planned nutrition unit spinoff

Wed, 21 Oct 2026 07:47:21 -0400

Investing.com -- Abbott (NYSE:ABT) reported third-quarter results that met earnings expectations and slightly exceeded revenue estimates, though shares are down around 1.4% premarket on Wednesday after the company also revealed plans to separate its Nutrition business.

The healthcare company posted adjusted earnings per share of $1.42, matching analyst estimates, while revenue of $13.01 billion edged past the consensus estimate of $12.99 billion. Revenue increased 14.5% on a reported basis and 7.0% on a comparable basis compared to the third quarter of 2025.

The company reaffirmed its full-year 2026 adjusted EPS guidance range, tightening it to $5.50 to $5.55, with a

Abbott beats revenue estimates, shares slide amid planned nutrition unit spinoff

Wed, 21 Oct 2026 07:47:21 -0400

The company reaffirmed its full-year 2026 adjusted EPS guidance range, tightening it to $5.50 to $5.55, with a

Form 8-K ABBOTT LABORATORIES For: Oct 21

Wed, 21 Oct 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20261021/27213131.html

Abbott (ABT) Reports In-Line Q3 EPS

Wed, 21 Oct 2026 07:32:09 -0400

Abbott (NYSE: ABT) reported Q3 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $13.01 billion versus the consensus estimate of $12.99 billion.

For earnings history and earnings-related data on Abbott (ABT) click here.

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Wed, 21 Oct 2026 07:30:00 -0400

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
Expands portfolio with key new product

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Wed, 21 Oct 2026 07:30:00 -0400

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
Expands portfolio with key new product

Abbott plans to spin off its nutrition unit as a standalone public company

Wed, 21 Oct 2026 07:26:42 -0400

Abbott (NYSE: ABT) announced plans to separate its Nutrition business into an independent, publicly traded company, with the transaction expected to be completed by the end of 2027.

The Nutrition unit, which carries brands such as Ensure, Similac, PediaSure, Pedialyte and Glucerna, generates approximately $8.5 billion in annual sales. The business employs about 16,000 people across 14 manufacturing sites.

Abbott intends to execute the separation through a tax-free distribution of shares in the new Nutrition company to existing Abbott shareholders. Upon completion, shareholders would hold equity in both companies. Abbott said the combined dividend paid by the two entities is expected to

Abbott plans to spin off its nutrition unit as a standalone public company

Wed, 21 Oct 2026 07:26:42 -0400

Abbott (NYSE: ABT) announced plans to separate its Nutrition business into an independent, publicly traded company, with the transaction expected to be completed by the end of 2027.

Abbott plans to spin off its nutrition unit as a standalone public company

Wed, 21 Oct 2026 07:26:42 -0400

Abbott (NYSE: ABT) announced plans to separate its Nutrition business into an independent, publicly traded company, with the transaction expected to be completed by the end of 2027.

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

Wed, 21 Oct 2026 07:25:00 -0400

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies
The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

Wed, 21 Oct 2026 07:25:00 -0400

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies
The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure

Abbott (ABT) call put ratio 1.1 calls to 1 put into quarter results

Tue, 20 Oct 2026 11:02:28 -0400

Abbott (NYSE: ABT) October 23 weekly call option implied volatility is at 77, November is at 37; compared to its 52-week average of 19 to 38. Call put ratio 1.1 calls to 1 put into the expected release of quarter results before the bell on October 21.

Abbott (ABT) call put ratio 1.1 calls to 1 put into quarter results

Tue, 20 Oct 2026 11:02:28 -0400

UBS Reiterates Buy Rating on Abbott Labs (ABT) on EPD Strength

Mon, 19 Oct 2026 09:33:42 -0400

UBS analyst Patrick Wood reiterated a Buy rating and $125.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "EPD deserves more attention given the biosimilars pipe: of ABT's divisions we think EPD gets the least focus, despite often contributing 15-20% of group organic growth and having what we think is the best ROIC across the group (c. 35% post-tax)...in short we think we can get to street numbers (+7% organic) on the base business alone (c. +2% price / mix, +5% volumes). Layering the biosimilars pipe on top, we get closer to +10% organic growth in 2028e and 2029e,

StoneX Reiterates Buy Rating on Abbott Labs (ABT)

Fri, 16 Oct 2026 10:05:02 -0400

StoneX analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "Abbott Labs is scheduled to report 3Q results on October 21 BTO. We continue to forecast 3Q 2026 constant currency revenue of $13.089 billion (up 15.1%), with a slightly improved FX impact assumption of approximately (1.1%) (was (1.5%)) for an as-reported revenue estimate of $13.011 billion (up from $12.983 billion). Our Adjusted EPS estimates are unchanged. Consensus currently sits at $1.42 in adjusted EPS on revenue of $12.996 billion for the quarter. Last quarter, management guided to annual Adjusted EPS

TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H'

Fri, 16 Oct 2026 09:32:28 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented: "The Stage is Set for a Stronger 2H; We expect ABT to make a return to +M-HSD% sales growth in 3Q26 alongside multiple business recoveries (Core Dx & Nutrition) and accelerations (Cancer Dx and Electrophysiology). We tweak our 3Q/4Q EP estimates to account for broad LAAC market softness, but strong P&L results and an in-line 3Q with multiple catalysts playing out should keep guidance on the table and allow the stock to work higher."

For an analyst ratings summary and ratings

U.S. MedTech stocks: Q3 earnings preview